RE: Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-1919 Oct 2022 23:36
This is the para referencing SNG001
"Type I IFNs—In order to trigger the innate immune response, recombinant IFN-
Is, such as IFNa and IFNß, have been widely used in the past and studied in cancer
treatment alone or in combination with chemotherapeutics, both in oncology and onco-
hematology [149–154]. Recombinant IFN-Is are also being actively studied as therapeutic
approaches for COVID-19; in particular, a few studies have assessed the effectiveness
of nebulized IFNß-1a in COVID-19 hospitalized patients. These studies highlight that
receiving IFNß-1a is correlated with earlier recovery and lower incidence of adverse events
and has also been associated with clinical improvement in one study [155,156]. Recent
studies and a meta-analysis underline the positive effects of IFNß administration combined
with other antivirals, such as ribavirin in the early days of virus spreading, resulting in
higher survival rates, lower mechanical ventilation rates, enhanced viral clearance and an-
tiviral response [157,158]. Similarly, a multicenter cohort study investigated the correlation
between early administration of IFNa-2b and antivirals (lopinavir/ritonavir) with a lower
mortality rate when compared with antiviral treatment alone; conversely, patients with
late administration of IFN experienced increased mortality and delayed recovery among
survivors [159]."
There is a considerable amount of literature out there re INF vs Cancer. Understand one of the biggest challenges has been the side effects of systemic inf application in large enough quantity to affect tumors. Maybe they could try putting it directly in to the lungs?
Sign In
Follow the stocks
